AI-generated · cited to primary sources · not investment advice
Beta Drugs Ltd (BETA) Nov 2025 Filing Analysis
Does management do what it says?
The company achieved a total revenue of INR 385 Cr in FY26 (Branded 140 + CDMO 149 + Exports 71 + Others 25). Compared to FY25 revenue of ~INR 300 Cr (implied by 25% growth target from FY24's 240 Cr), the actual growth exceeded 28%. (1 exceeded, 2 missed, 2 met across 5 tracked commitments)
“So, actually, we never gave Rs.450 crores. We said we will continue to grow at 20% to 25%. Although this time the growth was only 13%, but we will be having strong numbers for the next half of the year.”
The company has increased its international presence to over 46 countries as of FY'25, surpassing the specific expansion targets for the half-year. (1 exceeded, 1 met, 2 missed across 4 tracked commitments)
“So, that is why we know that as compared to first half, if we did Rs.43 crores, we will be crossing Rs.100 crores of top line in exports for next half.”
See the full cited Management analysis of Beta Drugs Ltd
What could break the thesis?
The risk is intensifying in terms of complexity as the company targets highly regulated markets like Europe. While the EU audit was delayed, it is now scheduled for Q1 FY27 (Jan-Mar), representing a critical binary milestone. (1 intensifying)
“The Europe approval has been delayed for long, but finally it will happen in the first quarter of next year... We will be the first cytotoxic suspension plant to be inspected by Europe.”
See the full cited Risk analysis of Beta Drugs Ltd
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.